In previous publications from this laboratory we suggested the use of radioprotective drugs in a sustained-release fo rm as a practical way to cope with their high toxicity and quick metabolism and excretion. Cysteine and cysteamine, well-established radioprotectants, were used as model drugs and compressed at various concentrations (0-65%) into an insoluble tablet matrix, composed of ethylcellulose and stearic acid at various ratios and compression pressures. We demonstrated in vitro that when the release rate of the radioprotectants was measured under nitrogen, the kinetic data conformed with the Higuchi square root of time equation, indicating that the release of both drugs correlates with Higuchi's diffusional mechanism. In the present in vivo study, tablets con taining cysteine or cysteamine in a slow-release matrix were implanted, into the stomachs of female rats. The rats were irradiated at various time intervals up to 12 h after implantation and their survival recorded daily. Utilizing a 1:3 ratio of ethylcellulose: stearic acid as a matrix, the protective effect of the drugs was remarkable eight hours after tablet implantation. The results reported indicate that slow-release tablet formulation is a possible method for delivering of radioprotective drugs over an extended period of time.
Introduction
The search for new radioprotective agents during the past two decades joined efforts on syntheses of new com pounds, hoping to get chemicals with dosemodifying effects more profound than those of the classic radioprotectants cysteine and cysteamine. Such radioprotectants have to be adm inistered short ly before exposure to radiation, are toxic to mam mals, and are rapidly excreted and degraded [1] . Some of them produce a state of shock when injected at radioprotective dose levels, as they are hypoten sive, vasodilative and cause enhancem ent in vascular permeability [2] . One way to keep a high serum level of these drugs without actually exposing the subject to high doses at any particular tim e, is to use a phosphorylated drug, which is then dephosphorylated to its active form in vivo. A nother approach, developed in this laboratory, is to compress the radioprotective drug in a slow-releasing matrix [3, 4] .
Previous in vitro studies from our laboratory pre sented kinetic data on the release of cysteine and cysteamine from an insoluble matrix. The data con formed with the Higuchi square root of time equa tion [4] and allowed us to select the best matrix for in vivo studies as far as composition of the tablet and tabletation pressure were concerned. O ur prelimi nary in vivo studies dem onstrated that survival of rats irradiated 10 Gy at various time intervals after im plantation of such sustained-release tablets con taining 50% cysteine, was the highest when the tab lets were implanted into the rats' stomachs 8 h be fore the irradiation [3] , Due to the increasing need for sustained-release radioprotectants and the lack of new, less toxic ones, we undertook to investigate the radioprotective effect of two well-established radio protectants, cysteine and cysteamine, em bedded in controlled-released matrix, after their implantation into stomachs of rats, and subsequently exposed to whole-body gamma irradiation.
Materials and Methods
Sustained-release tablets containing the radiopro tective drugs cysteine or cysteamine were surgically implanted under ether anesthesia and careful elec trocoagulation into stomachs of female albine Lewis rats weighing 220-250 g each. In order to assure tab let uniformity, cysteine HC1 and cysteamine HC1 (Sigma, St. Louis, Missouri, U SA ), of the same par ticle size distribution, were used during the entire investigation. Just prior to pressing the tablets, both powders were dried and suspended under continuous stirring in m elted stearic acid USP XVI, in a Pyrex glass container. The mixture was continuously stirred even after heat rem oval, until complete solidifica tion, then granulated by a 20-mesh screen and mixed with various proportions of ethylcellulose (N type, having ethoxy content of 47.5-49.0% ) in a mortar. The ratio of ethylcellulose (Hercules N-100) to stearic acid (M erck, D arm stadt, Germ any) was 1:3. Various concentrations of cysteine (0-65%) and cysteamine (0 -25% ) were mixed with this matrix and were com pressed into cylindrical tablets of 13.1 mm in diam eter and a mean surface area of 400 mm2, weighing 500 mg each. A laboratory press having a vacuum KBr die was used, and the compact ing pressure was fixed at 4 tons throughout the study.
Tablet im plantations were perform ed between 8 -10 am, into 18-hour-starved rats. The rats and the tablets of each specific concentration were selected at random , and one tablet was im planted per rat. U nder anesthesia an incision was made in the mid line of the abdom inal body wall, the stomach ex posed and a 2 cm long cut was perform ed along its o uter curve. The selected tablet was then pushed through the cut with the aid of forceps, and the cut sutured using cat gut or silk threads. Electrocoagula tion was done carefully whenever necessary, to minimize bleeding, the body wall and the skin su tured and the anesthetic removed. The moment each rat turned on its abdom en was recorded, and the irradiations were done at fixed time intervals after this time point.
For the whole-body irradiation the rats were placed into a circular case m ounted around a radioactive source, with 86 cm animal-to-source dis tance. They were exposed at 0.75 Gy/minute, to a total body irradiation of 10 Gy (6(lCo unit, model 150 A , Atomic Energy of Canada). The radiation dose was m onitored and confirmed by thermoluminiscent dosim eters. Eight to ten rats were pooled in each experim ental group. A fter irradiation the rats were divided into cages, two per cage, received Purina pellets and w ater ad libitum, and were kept in a wellventilated room at 20 °C. Daily survival was moni tored for fourteen days post-irradiation, and express ed graphically. Survival rates were obtained from those curves.
Results
The first factor determ ined in this study was the radiation dose, aimed at defining a dose which will kill the unprotected rats in less than 14 days, so that any differences betw een the m atrix-treated and the drug-treated rats will be noticeable on day 14 after irradiation. Eight, 10 and 15 Gy were used, but while 8 Gy was too low a dose (50% of the untreated rats survived over 14 d), and 15 Gy killed all the rats within 8 days, 10 Gy was chosen for subsequent ex perim ents (Fig. 1) .
The second factor studied was the length of the radioprotective effect. This was perform ed by im planting into the rats' stomachs tablets with 50% cys teine HC1, and irradiating them 2, 6 , 8 or 18 h after implantation. Fig. 2 dem onstrates that out of the four time-intervals (betw een im plantation and irradi ation) tested, 8 h is the optim al one. A pparently 2 and 6 h were too short for a protective dose to be released, and 18 h was a too-long time lapse to retain radioprotective activity. T herefore, 8 h was chosen as the time interval for all other subsequent experi ments with cysteine protection.
The dose of the cysteine tablets implanted 8 h be fore irradiation was also m onitored, and even though only two concentrations were actually used, it was clear that the higher concentration (65%) was al ready less effective than the 50% , as it forced reduc- tion in weight of the slow-release m atrix, causing a quicker release and consum ption of the drug. 50% seems to be a practical concentration of cysteine to be used in such tablets (Fig. 3 ). Due to the high toxicity of cysteamine, only con centrations below 25% of it were used in our study. While concentrations below 12% did not increase the survival rate, as compared to controls, concentra tions above 15% were already toxic. We concluded that under our experimental conditions (10 Grays and 8 h interval), 15% cysteamine was the optimal concentration for its experimental use as a radio protectant (Fig. 4) . 
Days after Irradiation

Discussion
Although it has been established that cysteine and cysteamine protect against gamm a-irradiation, these drugs are toxic to all mammals investigated [5] . The Dose Reduction Factor (D R F) for both cysteine and cysteamine in mice is 1.7, their LD50 values in rats are 700 and 130 mg/kg and their protective doses in rats are 1200 and 600 mg/kg, respectively [6, 7] . For comparison, the LD 50 of WR-2721, a thiophosphate derivative of cysteine, is 550 mg/kg, while its protec tive dose is 400 mg/kg, 80% of its LD 50. At that dose it has a whole body D R F of 2.6 [8] .
To the best of our knowledge, no previous results on radioprotection of animals given sustained-release radioprotective tablets have been published so far. The goal of our study was, therefore, not only to achieve an effective prolonged supply of two wellestablished radioprotectants, but also to supply the drugs in a less toxic modality. Cumulative toxicity of repeated iv doses of such drugs introduce some diffi culty in studying protection against radiation. Hence, repeated injections of split doses of cysteine and cysteam ine were shown to be better tolerated than one large dose of the same drugs, provided that an inter val of a few hours is m aintained between administra tions. Prolonged supply was shown to have very low toxicity: when cysteamine was supplied to rats in the food in concentration of up to 0.5% for 27 days, no toxic reactions were noticed [9] , but its protective effect against radiation was low.
W hen preparing the tablets we noticed that the efficiency of the two radioprotectors correlated with their toxicity. While cysteine could be compressed and used in concentrations of up to 65% , cysteamine could not be given to rats in concentrations exceed ing 20% , due to its high toxicity. We actually limited further experim ents to 20% of the latter drug, when noticing that in higher concentrations its adverse reactions were even m ore profound when pressed in tablets containing over 75% of stearic acid. As fre quent adm inistration of cysteine and cysteamine to hum ans is impractical -we suggest this slow re leased modality which lowers the toxicity and retains part of its radiation protection ability as compared to conventional drug administration.
We chose rats for stomach im plantation because in this model the tablet matrix does not pass from the stomach to the intestine for a few days, allowing con trolled dissolution of its active ingredients in a nar row range of pH values, thus isolating the dissolution rate factor from other factors involved in the stomach-to-intestine transfer of food. A nother justifica tion of this model is its simplicity: hardly any of the negative control rats (operated but not irradiated) died, and complications due to the operation were minimal. O ut of a random selection of 27 rats, none developed any visible ulceration [9] .
Even though in our preliminary studies we followed-up the rats for 30 days post irradiation, we found out that a 14-day follow-up after irradiation is enough for our com parative studies as this was the critical period of time for acute radiation damage.
For that reason, the result of the studies reported here were not presented beyond this time period. In order to further justify this decision, the radiation dose per rat was increased to 10 Gy, as compared to 6 -8 Gy which might have been sufficient in similar experiments with rats followed up for 24-30 days after irradiation [1] , The best hem atopoietic radioprotective effect was obtained in this study using tablets containing 50% cysteine and transplanted 8 h before irradiation. N either a higher (65% ) concentration of the drug nor shortening the time interval between implantation and irradiation exhibited any superior protection. Cysteamine showed a very poor protection, if at all, as the standard deviation for the different tablet con centrations from the control tablets was very small. The m ajor reasons for cysteine's better protection as compared to cysteamine are that under identical ex perimental conditions cysteine dissolves slower and is more stable in solution, consequently enhancing bioavailability to the irradiated cells. As noticed in our previous publications [3, 4] the kinetic data of the drugs' dissolution conformed with the Highuchi's square root equation and first order release. Because both plots were linearily acceptable, a statistical m ethod for release mechanism identification was used, showing that am inothiol release from the m at rix tablets follows the Higuchi square root equation, with solvent penetration (which also follows the square root of this relationship) being the rate-limiting factor in the release process. This relationship between the cumulative am ount of the drug released and the square root of time is linear until 80% of the active com ponents are released from the matrix.
This study suggests that simple pharmaceutical modifications of the drug dosage form can be used for prolonged hem atopoietic protection of human subjects against internal contam ination with radionuclides or against external irradiation during radiation therapy and at various emergency condi tions.
